Drug intelligence / Profile preview

BTM-3659

Development stage: Preclinical
Lead developer: Bantam Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

BTM-3659 is an orally bioavailable small molecule therapeutic under development by Bantam Pharmaceutical for the treatment of hematological and solid tumors. It is part of a pipeline of compounds designed to target mitochondrial dynamics and homeostasis. By selectively modulating these mitochondrial processes, the drug aims to induce apoptosis specifically in cancer cells. BTM-3659 represents a distinct chemical series from Bantam's lead candidate, BTM-3566, and is currently in the early drug discovery and preclinical stages of development.

Beyond the preview

Go deeper on BTM-3659.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BTM-3659.

Explore the full profile